| 1 |
33075481 | Comprehensive in-silico analysis of damage associated SNPs in hOCT1 affecting Imatinib response in chronic myeloid leukemia. | 2021 Jan |
3 |
| 2 |
34128532 | Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia. | 2021 Nov 2 |
1 |
| 3 |
30734690 | Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. | 2019 |
2 |
| 4 |
28762371 | Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. | 2018 May 22 |
2 |
| 5 |
29427770 | Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. | 2018 May |
3 |
| 6 |
29567937 | Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours. | 2018 Mar 23 |
12 |
| 7 |
29808796 | Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. | 2018 May 15 |
1 |
| 8 |
30138624 | Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel. | 2018 Oct |
1 |
| 9 |
30262695 | Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. | 2018 Sep |
1 |
| 10 |
28154092 | Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. | 2017 May |
7 |
| 11 |
28286932 | hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. | 2017 Apr |
2 |
| 12 |
28289867 | Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. | 2017 Apr |
2 |
| 13 |
28843219 | Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients | 2017 Aug 27 |
8 |
| 14 |
26841308 | Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies. | 2016 Jul |
1 |
| 15 |
25039279 | Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells. | 2015 Jan |
4 |
| 16 |
25358338 | Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia. | 2015 |
3 |
| 17 |
26108972 | Lysosomal Sequestration Determines Intracellular Imatinib Levels. | 2015 Sep |
2 |
| 18 |
26122430 | OCT1 and imatinib transport in CML: is it clinically relevant? | 2015 Oct |
7 |
| 19 |
26300393 | Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. | 2015 Oct 15 |
1 |
| 20 |
26343356 | Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. | 2015 Aug |
1 |
| 21 |
26546461 | A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. | 2015 Dec |
2 |
| 22 |
24215657 | OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. | 2014 Apr |
4 |
| 23 |
24352644 | Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). | 2014 Feb 15 |
4 |
| 24 |
24469953 | Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. | 2014 Mar |
1 |
| 25 |
24589908 | The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. | 2014 Aug |
3 |
| 26 |
25087954 | Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells. | 2014 |
1 |
| 27 |
25568846 | OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. | 2014 Dec |
6 |
| 28 |
23223357 | The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. | 2013 Jan 24 |
3 |
| 29 |
23766461 | Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib? | 2013 Jun 13 |
2 |
| 30 |
24117365 | A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. | 2013 Dec |
4 |
| 31 |
21886172 | Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. | 2012 Mar |
4 |
| 32 |
22207690 | Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. | 2012 Jun |
13 |
| 33 |
22508387 | Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. | 2012 |
3 |
| 34 |
22531634 | Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. | 2012 May 22 |
2 |
| 35 |
22677017 | Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. | 2012 Oct |
3 |
| 36 |
22781602 | [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia]. | 2012 Mar |
1 |
| 37 |
22883199 | [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia]. | 2012 May 29 |
1 |
| 38 |
23272163 | SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. | 2012 |
2 |
| 39 |
20971815 | OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. | 2011 Feb |
2 |
| 40 |
21163869 | Drug transporters and imatinib treatment: implications for clinical practice. | 2011 Feb 1 |
2 |
| 41 |
21185600 | Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. | 2011 Aug |
3 |
| 42 |
21252289 | Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. | 2011 Mar |
1 |
| 43 |
21663515 | Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. | 2011 Oct |
1 |
| 44 |
21853672 | [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience]. | 2011 |
5 |
| 45 |
20147974 | Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. | 2010 Apr |
7 |
| 46 |
20421539 | Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. | 2010 Jun 1 |
4 |
| 47 |
20445576 | hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. | 2010 Jun |
1 |
| 48 |
20634379 | The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. | 2010 Oct 14 |
3 |
| 49 |
20811406 | OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. | 2010 Nov |
1 |
| 50 |
19621544 | Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. | 2009 Apr |
2 |